Y-Mabs Therapeutics Inc
YMAB
Get informed when a big investor buys or sells
+ FollowMarket Cap$391.22M
Close$
$18.99
120.5% upside
Current Fair Value
120.5% upsideUndervalued by 120.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $391.22 Million |
|---|---|
| Enterprise Value | $332.06 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.67 |
| Beta | 0.53 |
| Outstanding Shares | 45,318,028 |
Return
| Return on Equity | -25.40% |
|---|---|
| Return on Assets | -18.96% |
| Return on Invested Capital | -28.27% |
Valuation & Multiples
| P/E Ratio | -25.63 |
|---|---|
| PEG | 39.44 |
| Price to Sales | 8.61 |
| Price to Book Ratio | 8.61 |
| Enterprise Value to Revenue | 3.89 |
| Enterprise Value to EBIT | -12.46 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 5.47% |
|---|---|
| Total Calls | 24,000▼ 37.50% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 61.57%▼ 2.29% |
|---|---|
| Total Invested | $125.85M▼ 1.38% |
| Investors Holding | 97▼ 7.00% |
ESG Score
No data
About Y-Mabs Therapeutics Inc
125 employeesY-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, inc...